ProCE Banner Activity

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease


Download this slideset from a live meeting series for the multidisciplinary team to get up to date on the latest clinical data informing optimal use of novel therapies in the treatment of advanced HR+/HER2- high-risk early breast cancer and metastatic breast cancer, including management of key adverse events associated with novel agents.

Released: January 12, 2024



Carey Anders

Carey Anders, MD

Professor of Medicine, Division of Medical Oncology
Division Chief of Medical Oncology, Interim
Medical Director of the Duke Center for Brain and Spine Metastasis
Translating Duke Health Scholar
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Lilly.